BMS Receives FDA Approval for Transdermal Antidepressant
BMS Receives FDA Approval for Transdermal Antidepressant
Bristol-Myers Squibb Company (Princeton, NJ, www.bms.com) and Somerset Pharmaceuticals Inc. (Tampa, FL, www.somersetpharm.com) have received approval from the US Food and Drug Administration (Rockville, MD, www.fda.gov) for the “Emsam” selegiline transdermal system. Somerset Pharmaceuticals is a joint venture between Mylan Laboratories Inc. (Canonsburg, PA, www.mylan.com) and Watson Pharmaceuticals Inc. (www. Corona, CA, www.watsonpharma.com)
The product is the first transdermal patch for the treatment of a major depressive order in adults, reported Bristol-Myers Squibb in a company release. Emsam, a transdermal delivery system manufactured by Mylan for Somerset, is a monoamine oxidase inhibitor designed to relieve depressive symptoms.
BMS receives approval for new indication for Erbitux
Bristol-Myers Squibb also has received FDA approval for Erbitux (cetuximab), an IgG1 monoclonal antibody, for use in treating squamous cell carcinoma of the head and neck. This is the second indicated tumor type for Erbitux, which was previously approved as a combination therapy with irinotecan for treating colorectal cancer.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
